Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BILR 355 BS Formulations in Healthy Males
NCT02259868Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2005
- Primary completion
- Sep 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Boehringer Ingelheim. Started Jun 2005; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02259868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259868.